We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery Services

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK. Clients from across the globe will be able to access highly experienced teams specialising in these core drug discovery disciplines.

Both companies have outstanding drug discovery and development credentials. Together they are dedicated to delivering tailored solutions for clients and a more personalised service which ranges from target evaluation through to candidate nomination and predicted clinical pharmacokinetics and dose.

XenoGesis is a fast-growing provider of DMPK services, quantitative bioanalysis, in vitro pharmacology and modelling and simulation for human PK and dose prediction and the core team has a proven track record of delivery in drug discovery. BioAscent’s integrated drug discovery services are delivered by a team of expert biologists, medicinal chemists and compound management scientists co-located in state-of-the-art biology and chemistry laboratories.

Commenting, Richard Weaver, Managing Director of XenoGesis, said: “Our two businesses are closely aligned and offer great synergies for our clients, to provide a quick and effective route to drug discovery. There are very few organisations that genuinely can provide leading chemistry, biology and DMPK expertise collectively, with a track record of producing a series of viable candidates. Together we will provide a seamless relationship that allows for iterative drug design programmes, whilst reducing costs, improving timelines and increasing success rates for our clients.”

CEO of BioAscent, Paul Smith, added: “BioAscent has recently launched its integrated drug discovery services with a truly exceptional team of medicinal chemists and biologists, building on our established capabilities in compound management and our in-house Compound Cloud library. This strategic alliance with XenoGesis means we can also offer specialist DMPK capabilities and assay evaluation to identify - at the earliest possible stage in the drug discovery process - those compounds that a client can take forward. Together we seek to not just provide our clients with data, but also iterative feedback and advice, right from the start.”